Date: 2014-08-04
Type of information: Company acquisition
Acquired company: Reinnervate (UK)
Acquiring company: Reprocell (Japan)
Amount: undisclosed
Terms: * On August 4, 2014, Reinnervate, one of the leading companies in the field of 3D cell culture has been acquired by Reprocell of Shin-Yokohama in Japan. Reprocell, a pioneer in the field of induced pluripotent stem cell biology supplies iPSC-dervided Hepatocytes, Neurons and Cardiomyocytes as well as a range of media and reagents for stem cell culture. Reprocell also announced the acquisition of BioServe Inc of MD, USA, a leading supplier of human tissues and other biological samples with one of the largest commercial biorepositories in the world.
Details: Through the acquisitions of these companies located in Europe and in the United States, Reprocell Group will accelerate its iPS cell business through the following synergistic effects: (1) The Establishment of Global Distribution Network: Reprocell, Reinnervate and BioServe already serve the same types of customers including large pharmaceutical companies, biotechnology companies, major universities and medical institutions in Europe and the United States, respectively. The local sales and distribution expertise provided by Reinnervate and BioServe will help grow Reprocells’s market share in Europe and North America. Reprocell’s local presence in Japan and extensive distribution networks in Asia will help to accelerate sales of Reinnervate and BioServe products in Asia. (2) Technology synergy and new product introductions: - Next Generation iPS cell products. Through the combination of Reinnervate’s innovative 3D cell culture technologies and ReproCELL’s iPS cell technologies, the next generation of iPS cell products with better functionality and usability for customers will be developed and launched globally. - Patients-derived iPS Cell Products. Through the acquisition of BioServe, Reprocell will now have access to large variety of patient derived cells in disease areas such as Alzheimer\'s, Parkinsons and Cardiovascular disorders. This will accelerate the development and commercialization of diverse patient-derived iPS cell products where there is a rapidly growing market need.
Related: stem cell products
